MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
April 30 2024 - 7:30AM
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic, off-the-shelf, invariant
natural killer T (iNKT) cell therapies to treat cancer and other
immune-mediated diseases, today announced that the Company will
release its first quarter 2024 financial results before the market
opens on Tuesday, May 14, 2024. MiNK executives will host a
conference call and webcast at 8:30 a.m. ET that morning to discuss
the results and to provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (U.S. – NY), (800) 715-9871 (U.S.
& Canada)
Conference ID: 7888464
Webcast
A live webcast and replay of the conference call will be
accessible from the Events & Presentations page of the
Company’s website at
https://investor.minktherapeutics.com/events-and-presentations and
via https://edge.media-server.com/mmc/p/vc5onn9q.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic invariant natural killer T
(iNKT) cell therapies to treat cancer and other immune-mediated
diseases. MiNK is advancing a pipeline of both native and next
generation engineered iNKT programs, with a platform designed to
facilitate scalable and reproducible manufacturing for
off-the-shelf delivery. The company is headquartered in New York,
NY. For more information, visit https://minktherapeutics.com/ or
@MiNK_iNKT. Information that may be important to investors will be
routinely posted on our website and social media channels.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
From Apr 2024 to May 2024
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
From May 2023 to May 2024